OR WAIT null SECS
Jerry Martin is Senior Vice President and Global Technical Director, Biopharmaceuticals at PALL Life Sciences.
February 01, 2010
Maintaining asepsis and sterility is the primary challenge to implementing aseptic techniques and sterile processes in biopharmaceutical manufacture. Efforts to reduce the risk of microbial contamination of aseptically filled biotech products beyond their already low level represent engineering challenges, that don?t really compliment the progress in biotech R&D.